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1. Introduction 
Atherosclerosis is a progressive disease characterized by the accumulation of lipids and 
fibrous elements in the large arteries (Lusis, JA. 2000). Investigations into the genetics of 
atherosclerosis, along with biochemical approaches, have greatly advanced today 
knowledge of the mechanisms of this complex multifactorial disease (Lusis et al., 2004a, 
2004b; Lusis &Weiss , 2010). According to the oxidation hypothesis, oxidative stress is a key 
mechanism through which atherosclerosis as a chronic inflammatory disease develops. It is 
mediated by reactive oxygen species that alter the fundamental properties of cholesterol, 
cholesterol esters, and phospholipids on lipoproteins, as well as other proteins, to make 
them dysfunctional, immunogenic, and pro-atherogenic (Tsimikas et. al., 2009). Oxidative 
stress can be enhanced by non-enzymatic pathways, such as by copper and iron cations, as 
well as by enzymatic pathways, such as by lipoxygenases, myeloperoxidase, and NADPH 
oxidase. These pro-oxidant pathways are balanced by anti-oxidant mechanisms, such as 
anti-oxidant vitamins (alpha-tocopherol and carotenoids) present within lipoproteins, and 
anti-oxidant enzymes, such as superoxide dismutase and glutathione peroxidase. Many of 
these enzymes and products of oxidation can be measured in the circulation, including 
oxidized low-density lipoprotein, oxidized phospholipids, isoprostanes, and 
myeloperoxidase, and have been shown to predict the presence of cardiovascular disease 
(CVD) and incident cardiovascular events (Tsimikas et al., 2007, 2009).  
Human serum paraoxonase [(PON1); aryldialkylphosphatase (EC 3.1.8.1)] is associated with 
high density lipoprotein particles (HDL) responsible in part for the ability of HDL to prevent 
lipid peroxidation. The decreased serum paraoxonase (PON1) activity in patients with 
atherosclerosis disease may cause decreased HDL antioxidant capacity and therefore 
significantly influence the risk of the development of atherosclerosis (Aviram, M. 2004; 
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Nieminen et al., 2006; Shih DM. & Lusis AJ. 2009). The enormous between-individual 
biological variability in serum PON1 activity seems to be regulated mainly by genetic 
determinants. The paraoxonase gene family includes pon1, pon2 and pon3 genes which produce 
three enzyme paraoxonase 1 (PON1), paraoxonase 2 (PON2) and paraoxonase 3 (PON3). 
These genes are located on the long arm of chromosome 7 and they are structurally similar. 
They share about 70% of identity in nucleotide sequences and about 60% of identity in amino 
acid sequences. PON1 mRNA is expressed in the liver, and PON3 mRNA is expressed 
primarily in the liver but also in the kidneys. On the other hand PON2 mRNA is ubiquitously 
expressed in different kinds of tissues like kidneys, liver, lungs, small intestine, placenta, 
spleen, stomach and testicles and in the cells of the artery wall (including endothelial cell, 
smooth muscle cell and macrophages) (Draganov, DI.  La Du, BN. 2004; Ng et al., 2005). 
PON1 is a 354 amino acid long glycosylated protein and has an apparent mass of 43-47 kDa. 
The enzyme is synthesized in the liver and is secreted into plasma. In the plasma, PON1 is 
mainly bounded to high density lipoproteins (HDL) but also small amount of this enzyme 
was detected in very low-density lipoprotein (VLDL), and postprandial chylomicrons. 
PON1 has hydrophobic signal sequence on the N-terminal region, from which only the 
initiator methionine residue is removed, and this region is for the association of PON1 with 
HDL (Draganov, DI.  La Du, BN. 2004; Fuhrman et al., 2005.) PON1 possesses 
organophosphatase, arylesterase and lactonase activities and hydrolyzes different kinds of 
substrates (like paraoxon, chlorpyrifos oxon, diazoxon, sarin, soman, phenylacetate, 
tiophenylacetate homogentisic acid lactone, dihydrocoumarin, γ-butyrolactone and 
homocysteine thiolactone) (Draganov, DI.  La Du, BN. 2004; Ng et al., 2005).  PON1 is also 
well known to possess antioxidative and antiatherogenic activity, to protect HDL and low-
density lipoprotein (LDL) from oxidation, and to destroy biologically active oxidized lipids 
on lipoproteins and in arterial cells (Draganov, DI.  La Du, BN. 2004; Aviram, M. 2004). 
More than 160 polymorphisms of pon1 gene are known, and some of them have been 
recognized to affect PON1 concentration and activity (Deakin, SP.  James, RW. 2004; Costa 
et al., 2005). Two polymorphisms in the coding region of pon1 gene result in the substitution of 
amino acid glutamine with arginine at the position 192 (Q192R polymorphism, the exchange 
of codon CAA to CGA in exon 6) and in the substitution of amino acid leucine to methionine 
at the position 55 (L55M polymorphism, the exchange of codon TTG to ATG in exon 3) 
(Adkins et al., 1993). Q192 and R192 alloenzymes have a different affinity and catalytic activity 
towards numerous substrates, the R192 alloenzyme hydrolyzes paraoxon six times faster than 
Q192 alloenzyme while Q192 alloenzyme hydrolyzes sarin, soman and diazoxon faster than 
R192 alloenzyme (Deakin, SP.  James, RW. 2004). These two alloenzymes are also different 
in their ability to protect LDL from oxidation in vitro, Q192 alloenzyme is more efficient than 
R192 alloenzyme (Deakin, SP.  James, RW. 2004; Mackness et al., 1999). L55M 
polymorphism affects PON1 mRNA levels, concentration and enzyme activity. M55 
alloenzyme is associated with a lower level of PON1 mRNA, concentration and activity 
(Deakin, SP.  James, RW. 2004). These two alloenzymes are also different in protection of 
LDL against oxidation, where M55 alloenzyme shows to be more protective (Mackness et al., 
1999). In the promoter region of pon1 gene at least five polymorphisms were detected and -
108C>T polymorphism is one of them. This polymorphism affects pon1 gene expression, and 
enzyme concentration and activity. It is believed that -108C>T polymorphism is the main 
contributor to serum PON1 variation (accounting for 23-24% of total variation), while other 
polymorphisms in pon1 promoter region made little or no difference to serum PON1 levels 
(Deakin, SP.  James, RW. 2004; Leviev, I.  James, RW. 2000; Suehiro et al., 2000). 
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As it was mentioned earlier, PON2 is a ubiquitously expressed intracellular protein with a 
relative molecular mass of approximately 44 kDa (Ng et al., 2005; Li et al., 2003). PON2 has 
antioxidant properties, lowers the intracellular oxidative stress and prevents the cell-
mediated oxidation of LDL (Ng at al., 2005; Li et al., 2003). In the pon2 gene two common 
polymorphisms were identified. Alanine or glycine could be at the position 148 (A148G), 
and serine or cysteine could be at the position 311 (S311C). S311C polymorphism has been 
related with eg. coronary artery disease, ischemic stroke in patients with type 2 diabetes 
mellitus, Alzheimer’s disease and reduced bone mass in postmenopausal women (Ng at al., 
2005; Li et al., 2003). The mechanisms by which PON2 exerts its atheroprotective effects 
remain to be clarified. Large-scale epidemiologic studies are needed to further examine the 
relationship between PON2 genetic polymorphisms and risk for CVD (Shih, DM.  Lusius, 
AJ. 2009). 
Human PON3 is a '40-kDa protein primarily synthesized in the liver with biological activity 
similar to PON1. PON3 is a secreted protein associated with HDL in the plasma and can 
participate in the prevention of LDL oxidation. The PON3 protein may play a role, distinct 
from that of PON1, in the lipoprotein metabolism of the kidney. These characteristics link 
PON3 with a group of enzymes, such as PON1, platelet-activating factor–acetylhydrolase, 
and lecithin-cholesterol acyltransferase, which together may contribute to the 
antiatherogenic properties of HDL, but the role of PON3 in atherosclerosis needs further 
investigation (Reddy et al., 2001; Getz, GS.  Resardon, CA. 2004). 
Another lipoprotein-associated enzyme, the platelet-activating factor acetylhydrolase (PAF-
AH), also referred to as lipoprotein-associated phospholipase A2 (Lp-PLA2), is an enzyme (EC 
3.1.1.47) recently described as a potentially useful plasma biomarker associated with 
cardiovascular disease (Srinivasan, B.  Bahson, BJ. 2010; Koenig et al., 2004; Yamada et al., 
2000; Karasawa, K. 2006; Mallat et al., 2010). The biological role of Lp-PLA2 (PAF-AH) has 
been controversial, with contradictory antiatherogenic and proatherogenic functions. The 
antiatherogenic properties of Lp-PLA2 were first suggested because plasma PAF-AH might 
play an anti-inflammatory role in human diseases by preventing the accumulation of PAF (1-
O-alkyl-2-acetyl-sn-glycero-3-phosphocholine) and PAF-like oxidized phospholipids 
(Karasawa, K. 2006; Mallat et al., 2010; Mitsios et al., 2006). PAF is a biologically active 
phospholipid involved in diverse pathologies such as inflammation and atherosclerosis. PAF 
can activate various cell types including platelets. In the presence of PAF, platelets aggregate 
and degranulate, releasing biologically potent agents. PAF is hydrolyzed and converted to 
lysoPAF by the catalytic reaction of PAF-AH (Mitsios et al., 2006). The atherogenic role of Lp-
PLA2 comes from the observation that this enzyme can also produce lysophosphatidylcholine 
and oxidatively modified nonesterified fatty acids which could promote the pathogenesis of 
atherosclerosis (Karasawa, K. 2006; Mallat et al., 2010). Lysophosphatidylcholine is an 
important chemoattractant for macrophages and T cells, it induces migration of vascular 
smooth muscle cells, affects endothelial function, and increases the expression of adhesion 
molecules and cytokines (Garza et al., 2007; Tsimikas et al., 2009). 
Phospholipases A2 (PLA2s) comprise distinct sets of enzymes with different localizations:  
the intracellular (cytosolic) enzymes that are Ca2+ dependent (cPLA2), Ca2+ independent 
(iPLA2), or specific for PAF (intracellular PAF acetylhydrolase) and extracellular (plasma) 
enzymes, either associated with lipoproteins (Lp-PLA2) or secreted PLA2s (sPLA2) (Mallat et 
al., 2010). Extracellular (plasma) PAF-AH shares 41% sequence identity with intracellular 
(cytosolic) Type II PAFAH, whereas both enzymes show less structural similarity to Type I 
PAF-AH (Karasawa, K. 2006; Mitsios et al., 2006). Secreted PLA2s (sPLA2) represent a 
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diverse family of structurally related, disulfide-rich calcium-dependent secreted enzymes 
that hydrolyze the sn-2 position of glycerophospholipids generating potent lipid mediators: 
lysophospholipids and free fatty acids, including the precursor of eicosanoids, arachidonic 
acid. Extracellular levels of secreted PLA2s are increased in both plasma and inflammatory 
fluids in various inflammatory diseases ( Karabina et al., 2010; Mallat et al., 2010 ).  
The extracellular (plasma) enzyme Lp-PLA2 is a single polypeptide that originates mostly from 
cells of the hematopoietic lineage, primarily from monocytes/macrophages (Karabina et al., 
2010; Stafforini, DM. 2009). Lp-PLA2 (PAF-AH) exhibits unique substrate specificity toward 
PAF and oxidized phospholipids. In human plasma, PAF-AH activity is associated mainly 
with the apolipoprotein B (apoB)-containing lipoproteins and primarily with low-density 
lipoprotein (LDL). A small proportion of the circulating enzyme activity is also associated with 
high density lipoprotein and lipoprotein(a), an atherogenic lipoprotein particle that appears to 
be a preferential carrier of oxidized phospholipids in human plasma (Mallat et al., 2010; 
Wolfert et al., 2004; Karasawa, K. 2006). In plasma, approximately 80% of Lp-PLA2 is attached 
to low-density lipoproteins (LDLs), and the remaining 20% is linked to high-density 
lipoproteins (HDLs) and lipoprotein (a) (Garza et al., 2007). HDL protects LDL from oxidation 
and HDL-associated PAF-AH might be involved in this effect together with other HDL-
associated enzymes, including PON1 and lecithin-cholesterol acyltransferase (LCAT) . 
Dyslipidemia-induced decrease in the ratio of HDL-associated PAF-AH to the plasma PAF-
AH levels might thus lead to the promotion of atherosclerosis (Karasawa, K. 2006 ; Garza et al., 
2007). Many studies appeared on the role of lipoprotein–associated PLA2 and secreted PLA2s 
in atherosclerosis at the level of biology and epidemiology. It is still unclear whether these 
PLA2s act as true biological effectors of cardiovascular diseases in humans and whether they 
have proven utility as biomarkers of disease severity (Mallat et al., 2010). 
We explored relations between serum PON1 and PAF-AH activities as well as the 
distribution of polymorphisms of pon1 and pon2 genes and cerebral atherosclerosis in well-
characterized groups of patients with angiografically assessed severe stenosis of cerebral 
arteries and matched control no-stenosis group.  
2. Patients and methods  
2.1 Patients 
The study comprised 119 patients, 35 women and 84 men with symptoms of cerebrovascular 
insufficiency and stenosis of carotid artery more than 50% of the lumen. Among them, 87 
(73.1%) had transitory ischemic attacks, 19 (16.0%) had suffered a cerebrovascular insult 
with motor deficit 5-9 months previously, and 13 patients (10.9%) had headache and vertigo 
with carotid bruit. All patients were examined by neurologists and referred to Doppler 
examination. At the Doppler examination, all of them had stenosis of one or both carotid 
arteries more than 50% of the arterial lumen and were preceded to digital subtraction 
angiography (DSA) and possible endovascular carotid PTA/stent treatment. Based on the 
angiographic findings, for the purpose of present investigation they were divided in two 
groups. The first group consisted of 73 patients, 25 female, median age 67 years (range, 41-79 
years) and 48 male, median age 65 years (range, 46-83 years) with a moderate degree of 
carotid extra cranial stenosis between 50% and 69% of the arterial lumen. In this group there 
was no intracranial stenosis of cerebral arteries. The second group consisted of 46 patients, 
10 female, median age 67 years (range, 46-78 years) and 36 male, median age 68 years 
(range, 54-78 years) in whom stenosis between 70-99% or obliteration of the carotid artery 
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was angiographically determined. In this group, intracranial stenosis less than 50% of the 
lumen of carotid arteries in three patients were found. 
The control no-stenosis group consisted of 90 patients, 46 female, median age 60 years 
(range, 44-76 years) and 44 male, median age 63 years (range, 46-82 years) with suspected 
cerebrovascular symptoms, but with normal Doppler examination of the carotid arteries. 
Vertigo, headache and transitory vision problems were indications for Doppler examination 
for 72 patients (80%). Twelve out of 90 (13.3%) patients had had nonischemic 
cerebrovascular insult a few months or years priorly with new symptoms like headache, 
suspected motor deficit or vertigo. The remaining six patients (6.7%) had the same 
symptoms combined with the carotid bruit. All of them had normal appearance and normal 
hemodynamic results at Doppler examination of carotid arteries. The third group of 
patients, with Doppler established carotid stenosis between 1-49% of cerebral arteries, was 
not included in the present investigation. They were proceeded to other non-invasive 
carotid investigations like MR angiography or multislice CT angiography. 
All Doppler and DSA procedures were performed at the Institute for Diagnostic and 
Interventional Radiology of the Merkur University Hospital. Doppler examinations were 
performed at the center of excellence with more than 3,000 examinations per year. DSA was 
performed by the interventional radiologists skilled in neurovascular interventions.  
Smokers were defined as those reporting daily smoking. Obesity was defined in terms of the 
patient’s body mass index (BMI) calculated as weight in kg/height in m2 . 
The patients with the BMI  25 were considered overweight. Written informed consent was 
obtained from all subjects according to the guidelines of our Ethics Committee. 
This study was approved by the Ethics Committee of the Merkur University Hospital, 
Zagreb, Croatia.  
2.2 Samples  
Blood samples were collected by venopuncture after overnight fasting and under controlled 
pre-analytical conditions. Serum was prepared 30 min after blood collection into vacutainer 
tubes (Becton Dickinson) without additives by centrifugation at 3000 rpm for 15 minutes. 
Blood collected in EDTA-coated tubes was used for determination of pon1 and pon2 
genotypes while sera were analyzed for triacylglycerol, total cholesterol, LDL and HDL-
cholesterol concentrations and PON1 and PAF-AH activities.  
2.3 Methods 
2.3.1 Serum triacylglycerol, total cholesterol, LDL and HDL cholesterol assays 
Serum triacylglycerol and total cholesterol were measured by enzymatic PAP- method. HDL-
cholesterol was measured with direct method based on selective inhibition of the non-HDL 
fractions by means of polyanions. A homogeneous assay for the selective measurement of LDL-
cholesterol in serum was used. All measurements were performed on fresh sera on the day of 
blood collection using standard commercial kits (Olympus Diagnostic GmbH, Hamburg, 
Germany) on the Olympus AU 600 analyzer (Olympus Mishima Co., Ltd., Shizuoka, Japan).  
2.3.2 Paraoxonase activity measurement 
PON1 paraoxonase activity was assessed by using paraoxon as the substrate in the presence 
of NaCl (NaCl stimulated activity) (Juretić et al., 2006). The assay was performed on 
Olympus AU 600 biochemical analyzer (Olympus Mishima Co., Ltd., Shizuoka, Japan) at 
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37°C, as previously described, with a minor modification (Grdić et al., 2008). Briefly, 15 μL 
of serum was added to 300 μL of reaction mixture containing 2.5 mmol/L paraoxon of ~90% 
purity, 2.2 mmol/L CaCl2 and 1.0 mol/L NaCl in 0.1 mol/L Tris– HCl buffer, pH 8.0. The 
release of p-nitrophenol from paraoxon was measured at 410/480 nm (ε410/480=17900 L/ 
mol cm) and the enzyme activity is expressed in international units per 1 L of serum and 
standardized against concentration of HDL-cholesterol . Serum samples were kept frozen at 
-80°C until the day of analysis. 
2.3.3 Paraoxonase polymorphisms determinations 
Polymorphisms of pon1 and pon2 genes were determined by the polymerase chain reaction 
(PCR) followed by restriction fragment length polymorphism analysis (PCR-RFLP) (Table 
1). The PCR reaction was performed in a Gene Amp PCR System 2720 (Applied Biosystems) 
PCR machine. Pon1 gene polymorphisms (Q192R, L55M and -108C>T) were determined by 
the method described by Campo et al., (Campo et al., 2004). with some modifications 
concerning the sequence of 1CT primer, annealing temperature and restriction enzyme for  
-108C>T polymorphism (Grdić et al., 2008; Grdić Rajković et al., 2011).  
Pon2 gene polymorphism (S311C) was determined by the method described by Sanghera et 
al. (Sangera et al., 1998) with a few modifications including the sequence of 2SC primer and 
annealing temperature (Grdić et al., 2011). Briefly, the amplification mixture (total volume 
25 μL) for each pon1 gene polymorphism and for pon2 gene polymorphism contained 250 ng 
of genomic DNA, 0.4 μmol/L of each primer, 0.2 mmol/L of each dNTP, 2mmol/LMgCl2, 
0.5 units of PlatinumTaqDNA Polymerase and 2.5 μL of reaction buffer (200mmol/L Tris–
HCl, pH 8.4 and 500mmol/L KCl). PCR reaction was carried out using the following 
procedure: the first step of predenaturation at 95 °C for 12 min, 35 cycles of amplification (30 
seconds at 94 °C followed by 30 seconds at specific primers annealing temperature and 60 
seconds at 72 °C), and the last cycle of final extension at 72 °C for 7 min. PCR was attenuated 
by lowering the temperature to 4 °C for at least 6 min. The primers, annealing temperatures 
and lengths of PCR fragments are given in Table 1. Endonuclease mixture for each 
polymorphism explored in this study (total volume 15 μL) contained 9 μL of amplified 
fragment, an appropriate buffer for each restriction enzyme and 4 units of BspPI (for pon1 
Q192R), 5 units of Hin1II (for pon1 L55M), 3 units of BsrBI (for pon1 -108C>T) and 3 units of 
DdeI (for pon2 S311C). For separation of restriction products electrophoresis on 4% agarose 
gel in TAE buffer (0.04 mol/L Tris–HCl, 5 mmol/L Na-acetate, 0.04 mmol/L EDTA, pH 7.9) 
and stained with ethidium bromide (final concentration was 0.5 μg/mL) were used. The 
length of RFLP fragments is given in Table 1.  
Determination of pon1 Q192R, pon1 L55M and pon1 -108C>T polymorphisms by the PCR-
RFLP procedure using specific restriction enzymes were described in details previously 
(Grdić et al., 2008, 2011). Briefly, for pon1 Q192R polymorphism undigested fragment (238 
bp) was detected in genotype QQ, digested fragments (175 and 63 bp) were detected in 
genotype RR, and both digested and undigested fragments (238, 175 and 63 bp) were 
detected in genotype QR. For pon1 L55M polymorphism undigested fragment (172 bp) was 
detected in genotype LL, digested fragments (103 and 69 bp) were detected in genotype 
MM, and digested and undigested fragments (172, 103 and 69 bp) were detected in genotype 
LM. For pon1-108C>T polymorphism undigested fragment (240 bp) was detected in 
genotype TT, digested fragment (212 bp) was detected in genotype CC, and both undigested 
and digested fragments (240 and 212 bp) were detected in genotype CT .  
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Poly-
morphism 
Primer °C 
Restrictio
n 
enzyme 
PCR 
fragme
nt 
RFLP 
fragments 
pon1  
Q192R 
1QR: 5′ TATTGTTGCTGTGGGACCTGAG 3′ 60  BspPI 238 bp Q allele:  238 bp 
 2QR: 5′ CCTGAGAATCTGAGTAAATCCACT 3′    R allele:  175+63 bp 
pon1  
L55M 
1LM: 5′ CCTGCAATAATATGAAACAACCTG 3′ 63  Hin1II 172 bp L allele:  172 bp 
 2LM: 5′ TGAAAGACTTAAACTGCCAGTC 3′    M allele:  103+69 bp 
pon1 -
108C>T 
1CT: 5′ 
AGCTAGCTGCCGACCCGGCGGGGAGGaG 3′ 68  BsrBI 240 bp 
C allele: 
 212+28 bp 
 2CT: 5′ GGCTGCAGCCCTCACCACAACCC 3′    T allele:  240 bp 
pon2 
 S311C 
1SC: 5′ ACATGCATGTACGGTGGTCTTATA 3′ 55  DdeI 265 bp S allele:  123+75+67 bp 
 2SC: 5′ AGCAATTCATAGAAAATTAATTGTTA 3′    C allele:  142+123 bp 
Table 1. Conditions for PCR-RFLP method. The lower case base “a” in pon1 -108CNT 1CT 
primer indicates a mismatch, introducing a restriction site for restriction enzyme BsrBI. 
Determination of pon2 S311C polymorphism by PCR-RFLP procedure using DdeI restriction 
enzyme was carried out as follows. The exchange of the nucleotide C with G results in 
substitution of codon TCT to TGT (exon 9 of pon2 gene), and with substitution of serine to 
cystein at position 311 (S311C, SNP ID rs7493). S and C alleles have a restriction site for DdeI 
restriction enzyme but the presence of codon TCT in S allele introduces an additional 
restriction site for this enzyme. The amplified fragment of 265 bp was digested in two 
fragments (142 and 123 bp) in both S and C allele. In the case of S allele 142 bp fragment is 
additionally digested in two fragments (75 and 67 bp). Fragments of 123, 75 and 67 bp were 
detected in genotype SS, fragments of 142 and 123 bp were detected in genotype CC, and 
fragments of 142, 123, 75 and 67 bp were detected in genotype SC.  
2.3.4 PAF-AH activity assay 
Platelet-activating factor acetylhydrolase (PAF-AH) activity was measured in plain serum 
with the new automated spectrophotometric assay (Azwell Inc., Auto PAF-AH, Osaka, 
Japan) at 37C (Kosaka et al., 2000). In the first phase, 2µL of serum was added to 240 µL of 
200 mmol/L HEPES (N-2-hydroxyethylpiperazine–N´-2-ethanesulfonic acid) buffer 
(Reagent 1), pH 7.6 and pre-incubated at 37ºC for 5 min. The reaction was started by adding 
80 µL of 20 mmol/L citric acid monohydrate buffer, pH 4.5 containing 90 mmol/L 1-
myristoyl-2-(4-nitrophenylsuccinyl)phosphatidylcholine (Reagent 2). The liberation of p-
nitrophenol was monitored at 405 and 505 nm at 1 and 3 min after the addition of Reagent 2 
using the automatic biochemical analyzer OlympusAU600 (Olympus Mishima Co., Ltd., 
Shizuoka, Japan). Enzyme activities are expressed in international units per liter of serum 
and standardized against concentration of LDL-cholesterol. Serum samples were kept 
frozen at -80°C until the day of analysis. 
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2.3.5 Quality control of measurements 
The Institute of Clinical Chemistry and Laboratory Medicine of the Merkur University 
Hospital has been accredited to ISO 15189, Medical laboratories - Particular requirements for 
quality and competence since 2007 (ISO 15189, 2008). Analytical methods for measurement of 
serum triacylglycerol, total cholesterol, LDL and HDL-cholesterol concentrations as well as for 
paraoxonase polymorphisms determinations used in this study have been accredited 
according to this norm (Flegar- Meštrić et al., 2010a).  Traceability of analytical methods is 
achieved through a manufacturer’s reference materials (calibrators) or reference methods for 
enzyme activities. Analyzer–based calibrations are routinely performed for compensation of 
systematic effects. Estimates of within-laboratory precision are provided by internal quality 
control data using commercial control sera (Olympus Diagnostic) for triacylglycerol, total 
cholesterol, LDL and HDL-cholesterol concentrations and pool serum samples for the 
paraoxonase and PAF-AH activities. Trueness estimates are based on the long-term results of 
external quality assessment (EQA) obtained by the participation of the Institute of Clinical 
Chemistry and Laboratory Medicine of the Merkur University Hospital in the National 
External Quality Assessment Scheme organized by the Croatian Society of Medical 
Biochemists and international EQA schemes for general and special medical biochemistry 
organized by Labquality - WHO Collaborating Centre for Education and Training in 
Laboratory Quality Assurance, FIN-00520 Helsinki, Finland (Flegar-Meštrić, Z. et al., 2010b). 
According to the requirements of the international standard ISO 15189, interlaboratory 
comparisons were performed for the paraoxonase polymorphisms determinations between the 
Institute of Clinical Chemistry and Laboratory Medicine of the Merkur University Hospital 
and Faculty of Pharmacy and Biochemistry, University of Zagreb, Croatia. Estimation of 
measurement uncertainties is done on the basis of the “Guide to the Expression of Uncertainty 
in Measurement” (GUM, 2005). The uncertainty components that we use are uncertainties 
related to calibrator, within-laboratory precision and trueness estimates based on the results of 
external quality assessment (EQA). The expanded measurement uncertainties (k=2) obtained 
for triacylglycerol, total cholesterol, LDL and HDL-cholesterol concentrations and pool serum 
samples for the paraoxonase and PAF-AH activities in the normal concentration range were 
4.8, 4.0, 8.0, 11.1, 4.2 and 3.8%, respectively. 
2.4 Statistical analysis 
The Mann-Whitney U-test was applied to evaluate the differences between the groups, with 
p< 0.05 considered statistically significant. The correlations between serum PAF-AH activity 
and concentrations of total and LDL cholesterol were estimated using Pearson's correlation. 
Chi-square test was used for comparisons of allele and genotype proportions. MedCalc 
statistical program (MedCalc Software Version 8.1.0.0, 2005 Frank Schoonjans for Windows, 
available at the website:www.medcalc.be/) was used. 
3. Results  
3.1 Patients 
The results of the Mann-Whitney U-test showed that, according to the demographic and 
lifestyle characteristics (age, body mass index), the control no-stenosis group matched the 
groups of patients with different degrees of cerebrovascular stenosis (Table 2). The chi-
squared test showed no significant differences between sex and cerebrovascular stenosis 
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subgroups (Yates corrected χ² =0.003, p=0.338 in the group with <70% of stenosis; Yates 
corrected χ² =0.023, p=0.638 in the group with >70% of stenosis) or smoking habits and 
cerebrovascular stenosis subgroups (Yates corrected χ² =0.001, p=0.478 in the group with 
<70% of stenosis; Yates corrected χ² =0.012, p=0.962 in the group with >70% of stenosis). The 
proportion of daily smokers in the group of patients with <70% of stenosis was 33.3% and 
32.6% in the group of patients with >70% of stenosis versus 25.8 % in control no-stenosis 
group. The mean values of the body mass index in all groups examined were more than 25 
kg/m2 , indicating overweight.  
3.2 Serum triacylglycerol, total cholesterol, LDL and HDL cholesterol concentrations  
Comparing the results obtained for the traditional risk factors (triacylglycerol, total 
cholesterol, HDL-cholesterol, LDL-cholesterol) between the groups of patients with 
cerebrovascular stenosis and control no-stenosis group using the Mann-Whitney univariate 
statistic method, significant differences were found for all serum lipid parameters (p<0.05) 
(Table 2).  
 
Parameter 
Control no-
stenosis 
group 
(N=90) 
Patients with cerebrovascular stenosis 
<70% of 
stenosis 
(N=73) 
P 
>70% of 
stenosis 
(N=46) 
P 
Age (years) 
61 
 (44-82) 
66  
(41 - 83) 
0.068 
68  
(46 - 83) 
0.160 
Body mass index 
(kg/m2 ) 
26.3  
(20.2 – 35.7) 
25.7  
(19.1 – 34.1) 
0.143 
26.5 
 (19.0 – 35.1) 
0.944 
Total cholesterol 
(mmol/L) 
6.3  
(4.2 – 8.4) 
5.4 
 (3.4 – 11.5) 
0.001 
5.7  
(3.5 - 9.6) 
0.000 
Triacylglicerol 
(mmol/L) 
1.39  
(0.34 – 4.14) 
1.75 
 (0.43 – 8.18) 
0.003 
1.66  
(0.71 – 5.09) 
0.026 
HDL- cholesterol 
(mmol/L) 
1.6 
 (1.0 – 3.1) 
1.3  
(0.7 – 2.3) 
0.000 
1.1  
(0.8 – 1.8) 
0.000 
LDL- cholesterol 
(mmol/L) 
3.9  
(2.6 – 5.9) 
3.6  
(1.8 – 6.3) 
0.021 
3.5 
 (1.2 – 8.4) 
0.001 
Table 2. Demographic and biochemical parameters for control no-stenosis group and 
patients with <70% and >70% of cerebrovascular stenosis. Results are given as medians, 
with ranges in parentheses. p values: significance level for difference between the group of 
patients with cerebrovascular stenosis and the control no-stenosis group tested by Mann-
Whitney test; p <0.05 was considered as statistically significant. 
3.3 Paraoxonase activity measurement 
Basal and stimulated PON1 activities differ significantly between patients group with stenosis 
and the control no-stenosis group, and HDL standardized basal and stimulated PON1 activity 
did not show statistical difference. Kolmogorov –Smirnov test for normal distribution reject 
normality for all examined data (Table 3) . There were no statistically significant relationships 
between basal and stimulated PON1 activity and examined lipid and lipoprotein parameters 
(tryacylglicerol, total cholesterol, HDL cholesterol, LDL cholesterol) (Table 4). 
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Paraoxonase  
(unit) 
Control no-stenosis 
group (N=90) 
Patients with 
cerebrovascular 
stenosis (N=119) 
p 
 Median (IQR) Median (IQR) 
Basal PON1 activity (U/L) 187 (137) 103 (180) 
0.0056 
 
NaCl –stimulated PON1 activity 
(U/L) 
379 (326) 213 (339) 0.0079 
HDL standardized  
basal PON1 activity (U/mmol) 
110 (125) 93 (142) 0.9390 
HDL standardized  
NaCl –stimulated PON1 activity 
(U/mmol) 
228 (238) 189 (310) 0.9605 
Table 3. Serum paraoxonase (PON1) activity and HDL standardized paraoxonase activity in 
control no-stenosis group and patients with cerebrovascular stenosis. Abbreviation: IQR, 
Interquartile range; p values: significance level for difference between the group of patients 
with cerebrovascular stenosis and the control no-stenosis group tested by Mann-Whitney 
test; p <0.05 was considered as statistically significant. 
 
 Correlation coefficient 
Control no-stenosis 
group (N=90) 
Patients with cerebrovascular stenosis 
(N=119) 
Basal PON1 activity 
r p r p 
Tryacylglicerol 0.1638 0.1229 0.0754 0.4211 
Total cholesterol 0.0105 0.9219 0.1534 0.1003 
HDL cholesterol 0.1278 0.2301 0.1146 0.2205 
LDL cholesterol -0.3067 0.3182 0.1201 0.1992 
 NaCl stimulated PON1 activity 
Tryacylglicerol 0.1587 0.1358 0.0691 0.4606 
Total cholesterol -0.0140 0.8956 0.1589 0.0844 
HDL cholesterol 0.1283 0.2281 0.1154 0.2173 
LDL cholesterol -0.1262 0.2359 0.1306 0.1623 
Table 4. Relationships between paraoxonase activity and serum lipids and lipoproteins 
levels. p <0.05 was considered as statistically significant. 
3.4 Paraoxonase polymorphisms determinations 
Genotype frequencies of pon1 and pon2 polymorphisms found in the group of patients with 
angiografically assessed stenosis of cerebral arteries vs. control no-stenosis group are 
presented in Table 5 and Figures 1-4. Observed and expected genotype frequencies of all 
examined pon1 and pon2 genes polymorphisms were in Hardy-Weinberg equilibrium. There 
were no statistically significant differences between genotype frequencies of pon1 and pon2 
(Table 5) as well as for the alleles frequencies in patients group vs. control no-stenosis group 
(p>0,05) (Table 6).  
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Genotype 
Control no-stenosis group 
(N=81) 
Patients with 
cerebrovascular stenosis 
(N=71) 
p 
n % n %  
pon1 L55M      
LL 33 40 32 45 P = 0,910 
LM 41 51 25 35  
MM 7 9 14 20  
pon1 Q192R      
QQ 38 47 33 47 P = 0,995 
QR 39 48 32 45  
RR 4 5 6 8  
pon1 -108C>T      
CC 22 27 18 25 P = 0,912 
CT 47 58 32 45  
TT 12 15 21 30  
pon2 S311C      
SS 44 54 45 63 P = 0,981 
CS 37 46 24 34  
CC 0 0 2 3  
Table 5. Genotype frequencies of pon1 and pon2 polymorphisms in control no-stenosis group 
and patients with cerebrovascular stenosis. Data are shown as number (n) and percentage 
(%) of individuals having a certain genotype; checked by Chi-square test.  
 
 
Fig. 1. Determination of L55M pon1 gene polymorphism by the PCR-RFLP procedure using 
Hin1II restriction enzyme. Lines 1- 4 LL, line 5 MM, and line 6 LM genotype. 
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Fig. 2. Determination of Q192R pon1 gene polymorphism by the PCR-RFLP procedure using 
BspPI restriction enzyme. Line 1 RR, line 2 QQ, line 3 QR, line 4 RR, line 5 QQ, and line 6 QR 
genotype. 
 
 
Fig. 3. Determination of -108C>T pon1 gene polymorphism by the PCR-RFLP procedure 
using BsrBI restriction enzyme. Line 1 CT, line 2 CC, lines 3, 4 CT, line 5 TT and line 6 CT 
genotype. 
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Fig. 4. Determination of S311C pon2 gene polymorphism by the PCR-RFLP procedure 
using DdeI restriction enzyme. Lines 1- 2 SS, line 3 CS, line 4 SS, line 5 CS, and line 6 CC 
genotype. 
 
Allele 
Control no-stenosis 
group 
Patients with 
cerebrovascular stenosis 
p 
n % n %  
pon1 L55M      
L 107 62 89 63 P = 0,9744 
M 65 38 53 37  
pon1 Q192R      
Q 115 66 139 70 P = 0,8477 
R 47 34 61 30  
pon1 -108C>T      
C 91 56 95 48 P = 0,1246 
T 71 44 105 52  
pon2 S311C      
S 125 77 160 80 P = 0,5980 
C 37 23 40 20  
Table 6. Allele frequencies of pon1 and pon2 polymorphisms in control no-stenosis group 
and patients with cerebrovascular stenosis. Data are shown as number (n) and 
percentage (%) of individuals having a certain allele; checked by Chi-square test. 
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3.5 PAF-AH activity assay 
The values of PAF-AH activity did not differ significantly between control no-stenosis 
group and group of patients with cerebrovascular stenosis (Table 7) while LDL standardized 
PAF-AH activity (U/mmol) showed significant difference. The PAF-AH activity showed 
significant relationship with total and LDL cholesterol in both groups studied (Table 8). 
 
 
Control no-stenosis 
group 
Patients with 
cerebrovascular stenosis 
 
Median (IQR) Median (IQR) p 
PAF-AH activity 
(U/L) 
405 (134) 414 (171) 0.769 
LDL standardized  
PAF-AH activity 
(U/mmol) 
99 (30) 119 (41) <0.0001 
Table 7. Serum Platelet-activating factor acetylhydrolase (PAF-AH) activity in groups 
studied. p values: significance level for difference between the group of patients with 
cerebrovascular stenosis and the control no-stenosis group tested by Mann-Whitney test; p 
<0.05 was considered as statistically significant. 
 
 
Correlation coefficient 
Control no-stenosis group 
Patients with cerebrovascular 
stenosis 
r p r p 
Tryacylglicerol 0.353 0.0006 0.153 0.1018 
Total cholesterol 0.417 <0.0001 0.591 <0.0001 
HDL cholesterol -0.360 0.0005 -0.006 0.9495 
LDL cholesterol 0.459 <0.0001 0.5879 <0.0001 
Table 8. Relationships between platelet-activating factor acetylhydrolase (PAF-AH) activity 
and serum lipids and lipoproteins levels. p <0.05 was considered as statistically significant. 
4. Discussion  
Atherosclerosis, a disease of large arteries, is the primary cause of heart disease and stroke 
(Lusis, JA. 2000). Epidemiological studies over the past 50 years have revealed various risk 
factors for atherosclerosis and cardiovascular disease, which can be grouped into factors 
with an important genetic component and those that are largely environmental (Gupta et al., 
2009; Lusis, JA. 2000). The results of our study indicated that significant changes associated 
with cerebrovascular stenosis could be the result of the environmental factors and 
demographic characteristics of the examined population, which is in accordance with 
previous studies that have investigated the atherosclerosis and the severity and extent of 
cardiovascular disease (Mallat et al., 2010; Costa et al., 2005; Granér et al., 2006). All groups 
examined in our study were characterized by a high frequency of cigarette smoking and 
overweight, which is consistent with the results of a previous large cross-sectional 
epidemiological study of Croatian population (Turek et al., 2001), and could be considered 
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as the possible risk factors that contribute to the increased risk of cerebrovascular stenosis 
(Flegar-Meštrić et al., 2007; Vrhovski-Hebrang et al., 2002).  
It has been reported that raised levels of atherogenic lipoproteins are a prerequisite for most 
forms of atherosclerotic disease (Mallat et al., 2010; Tsimikas et al., 2009; Lusis, JA. 2000). 
In our study, the median values obtained in the groups of patients with different degrees of 
cerebrovascular stenosis were for total cholesterol, LDL-cholesterol and tryacilglycerols 
higher and for HDL-cholesterol lower than the recommended values for prevention of 
atherosclerotic disease (De Backer et al., 2004), indicating a possible contribution of 
dyslipidemia to the risk of developing future stenosis of cerebral arteries.  
Today, the aim of cardiovascular risk prevention is to determine atherosclerotic disease 
activity and shift the present focus from identification of stenosis, which is a focal disease, to 
identification of patients with inflamed and rupture-prone plaque (Karabina et al., 2010). 
Numerous biomarkers have been proposed to better discern the vulnerability of plaque 
rupture, pathogenesis, or cardiovascular risk. Epidemiologic, genetic, and biochemical 
studies support an antiatherogenic role for paraoxonase (PON) 1. The two other members of 
the PON gene family, namely, PON2 and PON3, have also been reported to possess 
antioxidant properties and may exhibit antiatherogenic capacities as well (Shih, DM  Lusis, 
AJ. 2009). Previous studies have demonstrated that PON1 expression is down regulated by 
oxidative stress. In contrast, more recent studies have shown that PON2 expression is up 
regulated in response to oxidative stress-inducing agents, while PON3 expression remains 
unchanged (Ng et al., 2005). Although PON1 activity is determined genetically, various 
factors, such as diet, lifestyle and environmental factors, can influence PON1 activity (Ng et 
al., 2005; Gupta et al., 2009). Between individuals, there is an approximately 10- to 40-fold 
variation in PON1 activity (Gupta et al., 2009).  
Only a few studies have examined the relationship between PON1 activity and 
angiographically proven cardiovascular disease (Graner et al., 2006; Mackness et al., 2001). 
Our results indicated that basal and stimulated PON1 activities were significantly decreased 
in patients group with angiographically proven cerebrovascular stenosis (>50%) versus 
control no-stenosis group (p<0.05), and there were no statistically significant relationships 
between basal and stimulated PON1 activity and examined lipid parameters (total 
cholesterol, LDL-cholesterol, HDL-cholesterol and tryacilglycerols), p>0.05. Those results 
are in line with previous studies, indicating that PON1 activities toward paraoxon are lower 
in subjects with cardiovascular disease than in control subjects regardless of the PON1 
genotype. This would suggest that the quality of the PON1 enzyme is a more important 
factor in cardiovascular disease than the PON1 gene (Mackness et al., 2001).  
Polymorphisms in pon1 and pon2 genes (L55M and Q192R in pon1, and S311C in pon2) have 
been reported to be associated with the risk for the development of atherosclerosis as well as 
polymorphism in pon1 promoter region (-108C>T) (Pasdar et al., 2006; Granér et al., 2006).  
Paraoxonase-1 has several genetic polymorphisms that modify its activity and mass 
concentration. Hypothesized differences in the ability of the polymorphic forms to protect 
oxidation of LDL have led to numerous studies attempting to determine the relationship 
between PON1 polymorphisms and cardiovascular disease. The results of meta-analysis of 
88 studies on 4 PON polymorphisms [Q192R, L55M, and T(−107)C in the PON1 and the 
S311C in the PON2] suggested an overall weak association between the R192 polymorphism 
and CHD risk. Despite these limitations, this meta-analysis suggests that Q192R 
polymorphisms may increase the risk of CHD, but no significant effect for L55M, T(−107)C 
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and S311C polymorphisms (Wang et al., 2011). Additionally, it has been reported that no 
significant genotypic or allelic frequency differences between stroke cases and controls for 
any of the structural polymorphisms of the PON genes tested were found (Pasdar et al., 
2006).  
In our study, there were no significant differences in genotype or allele frequencies of pon1 
and pon2 genes between patients with stenosis of cerebral arteries and controls, indicating 
that there is no relationship between examined polymorphisms and reduced paraoxonase 
activity in patients group with angiographically proven cerebrovascular stenosis.  
The platelet-activating factor acetylhydrolase (PAF-AH) or lipoprotein-associated 
phospholipase A2 (Lp-PLA2) is among the multiple biomarkers that have been associated 
with an increased CHD risk (Karabina et al., 2010; Garza et al., 2007; Tsimikas et al., 2009; 
Reddy et al., 2009; Wolfert et al., 2004). A recent meta-analysis of 14 prospective 
epidemiologic studies involving more than 20,000 patients established a high relative risk 
for cardiovascular events with high Lp-PLA2.( Garza et. al., 2007; Ballantyne et al., 2007). 
The LDL-associated PAF-AH activity increases in parallel with the severity of 
hypercholesterolemia, thus one of the major factors that determines plasma levels of PAF-
AH is the rate of removal of LDL from the circulation (Karabina et al., 2010; Tsimikas et al., 
2009). In our study, the PAF-AH activity shows the most significant linear relationship with 
total cholesterol and LDL cholesterol in the control no-stenosis group and the group of 
patients with cerebrovascular stenosis. It has been reported that increased Lp-PLA2 activity 
is significantly related to incident cardiovascular disease (cardiovascular death, myocardial 
infarction, stroke, and transient ischemic attack) (Tsimikas et al., 2009; Mallat et al., 2010). In 
our study, the median serum PAF-AH activity did not differ significantly between patients 
with cerebrovascular stenosis and control no-stenosis group (median values 414 U/L versus 
405 U/L, p>0,05), which is consistent with results of our previous study (Flegar-Meštrić et 
al., 2003), while LDL standardized PAF-AH activity a showed significant difference between 
the patients with cerebrovascular stenosis and control group (median values 119 U/mmol 
versus 99 U/mmol, p<0,0001).  
Previous studies show that Lp-PLA2 is a unique inflammatory biomarker that plays a critical 
role in the development of atherosclerosis and may be involved in the causal pathway of 
plaque inflammation and plaque rupture (Munzel, T.  Gori, T. 2009; Cariquist et al., 2007). 
The association of Lp-PLA2 with cardiovascular risk among different population studies 
independent of classical risk factors makes the premise even stronger that Lp-PLA2 is 
involved in progression of atherosclerosis to advanced rupture-prone unstable plaques 
(Reddy et al., 2009) . As Lp-PLA2 is produced by macrophages and foam cells of 
atherosclerotic plaques that are numerous in unstable plaque, the differentiation between 
stable versus unstable plaque could be established by the presence of elevated Lp-PLA2 
(Reddy et al., 2009; Munzel, T.  Gori, T. 2009; Hiramoto et al., 1997; Zalewski, A.  
Macphee, C. 2005). However, the clinical utility of Lp-PLA2 activity for prediction of 
cardiovascular risk has to be explored in future studies. 
5. Conclusion 
The results of the present study show that basal and stimulated PON1 activities were 
significantly decreased in the patients group with cerebrovascular stenosis (group of 
patients with symptoms of cerebrovascular insufficiency and stenosis of carotid artery more 
than 50% of the lumen) versus control no-stenosis group (p<0.05). There were no statistically 
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significant relationships between PON1 activity and lipid parameters (total cholesterol, 
LDL-cholesterol, HDL-cholesterol and tryacilglycerols), p>0.05. According to the results 
obtained, we assume that decreased PON1 activities in patients with cerebrovascular 
stenosis may cause a decreased HDL antioxidant capacity and therefore contribute to the 
increased risk of the development of cerebrovascular atherosclerosis. However, there were 
no significant differences in genotype or allele frequencies of pon1 and pon2 genes between 
patients with stenosis of cerebral arteries and no-stenosis control group, indicating that 
changes in paraoxonase activity are determined by both genetic and environmental factors.  
Our results show the most significant linear relationship between PAF-AH activity and total 
cholesterol and LDL-cholesterol ( p<0.001) in the control no-stenosis group, as well as in the 
group of patients with cerebrovascular stenosis. The median serum PAF-AH activity did not 
differ significantly between the patients with cerebrovascular stenosis and control no-
stenosis group (p>0,05), while LDL standardized PAF-AH activity showed significant 
difference between both examined groups (p<0.0001). According to our results, the LDL-
standardized PAF-AH activity could be used as an additional discriminating biochemical 
indicator of cerebrovascular stenosis.  
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